Abstract

Jyoti Narvariya*, Sukhwant Singh and Jitendra Banveer

ABSTRACT

Increased complications and costs of marketing of innovative drugs focused greaterattention to the development of sustained release (SR) or controlled release (CR)drug delivery systems. Delivery systems extended release or controlled release ratecan achieve predictable and reproducible, the extended duration of activity for theshort time of life-drugs, reduced toxicity, and dose reduction request, the optimizedtherapy and better patient compliance. It is controlled primarily by the type and theproportion of the polymers used in the preparation. Metoprolol tartrate is acardioselective β1-adrenergic blocking agent used for acute myocardial infarction(MI), heart failure, angina pectoris and mild to moderate hypertension. It may alsobe used for supraventricular and tachyarrhythmias and prophylaxis for migraineheadaches. The objective of present work was to develop and evaluated oralsustained release matrix tablet of metoprolol tartrate prepared by the method ofdirect compression, using hydroxy propyl methyl cellulose (HPMC) and tragacanthpolymer alone and in combination at various concentrations. Pre-compressionparameters were evaluated. The tablets were evaluated for post-compressionparameters such as thickness, hardness, average weight, friability and In vitrorelease studies. No interactions were observed between metoprolol tartrate andexcipients from the Fourier transform infrared spectroscopy. The present researchwork was successful in improving the efficacy metoprolol tartrate oral therapy asthe drug release was extended for 24 hours thus reducing dosing frequency therebyimproving patient compliance. The study also revealed the applicability of HPMCK-15, tragacanth and PVP K25as rate-controlling polymers in matrix tablets. Thehydrophilic matrix of HPMC alone cannot control the release metoprolol tartrateeffective for 24 h while when combined with tragacanth, may slow down therelease of the drug and therefore, can be successfully employed for the formulationof matrix tablets SR. It may be concluded from the study that, the optimizedformulation F-1 was shown maximum drug release 99.78% in 24h of dissolution.